Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
“A new health economics analysis from Plus Therapeutics reveals that the CNSide® cerebrospinal fluid assay could slash overall healthcare costs related to leptomeningeal metastases by approximately 40% (ranging from 33% to 47%) through earlier detection, more precise treatment decisions, fewer hospitalizations, and better patient management. The study underscores the heavy economic burden of late-stage LM … Read more